Management of IRIS

  • Authors: Irini Sereti, MD, MHS; Philip Grant, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 4/1/16 (What's New)

Summary

  • Diagnosis and treatment of patients with IRIS should be managed by a specialist
  • Primary care providers should be aware that patients with low baseline CD4+ cell counts with a robust response to ART are at increased risk of IRIS
  • ART should not be delayed in patients for whom it is indicated, although guidance for patients with cryptococcal disease is evolving

Action required

Keywords: IRIS, Primary Care Considerations

©2018 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.